Combining OSI Pharmaceuticals’s Integrated Lead Discovery platform with BioTrove’s RapidFire mass spectrometry-based assay development, screening and analysis services, the agreement will enable customers to pursue challenging drug targets in a highly accurate, efficient and cost-effective manner.
The companies’s complete lead discovery service will provide access to OSI Pharmaceuticals’s Integrated Lead Discovery platform, enabling screening of large volumes of compounds against clients’s target assays. BioTrove’s mass spectrometry-based RapidFire platform, which enables label-free high-throughput screening using biological substrates, will be used to identify active compounds within chemical libraries.
Albert Luderer, president and CEO of BioTrove, said: “Our joint solution with OSI will enable increased research around novel targets for companies who may have crucial insights about disease progression, but do not specialize in large-scale high-throughput screening internally.”